EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Editas Medicine Hires Andrew Hack As CFO

Xconomy Boston — 

Editas Medicine, of Cambridge, MA, has hired former hedge fund manager Andrew Hack as its chief financial officer, the company said this morning. Hack was most recently a portfolio manager at New York hedge fund Millennium Management, where he focused on biotechnology, pharmaceutical, and medical device companies. Hack got his start as the co-founder of Reify Corp., a life science company, and later worked on Wall Street, at HealthCor Management, Carlyle-Blue Wave Partners, and the MPM BioEquities Fund. Editas inked a deal in May with Juno Therapeutics—the Seattle biotech that just announced a $1 billion deal of its own with Celgene—to use Editas’ gene editing technology CRISPR-Cas9 on Juno’s T-cell immunotherapy programs.